Illumina Blames 'Disappointing' Q3 on GWAS Decline, Order Delays, Reagent Kit QC Issues

CEO Jay Flatley said contributing to lower-than-expected revenue were delays in orders from ARRA-funded projects and quality-control issues with the firm's sequencing reagent kits.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.